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Introduction
Innate lymphoid cells (ILCs) represent a novel family of innate 
immune cells with lymphoid phenotypes, but lack rearranged anti-
gen receptors (1). ILCs can be divided into 3 groups, based on the 
expression of specific transcription factors, cell-surface markers, 
and signature cytokines (2, 3). Group 1 ILCs (ILC1s) have been 
defined as CD45+lineage–CD127+CD117–NKp44– cells and may 
produce IFN-γ and depend on T-bet for their functions (4). Group 2 
ILCs (ILC2s) are a population of lineage–CD127+CRTH2+ cells that 
preferentially produce type 2 cytokines such as IL-5 and IL-13 and 
require GATA3 (5). Group 3 ILCs (ILC3s) are lineage–CD127+CD117+, 
have the potential to produce IL-17 and/or IL-22, and are dependent 
on RORγt (6). ILCs have important effector functions in the early 
stages of immune responses against inflammation (7, 8), in tissue 
repair (9, 10), in the anatomical containment of commensals (11), 
and in maintaining epithelial integrity (12). Altered ILC populations 
in humans are also associated with the pathogenesis and progres-
sion of chronic infections and inflammatory diseases (3, 6, 13, 14).
ILC subsets exist in various tissues, with preferential tissue-
specific residence in human. For instance, ILC1s, including NK 
cells, mainly exist in fetal gut and liver; ILC2s are most preva-
lent in human peripheral blood, lung, and skin; and ILC3s are 
mostly present in human skin tissue, thymus, tonsils, BM, and 
gut (6, 15–17). Due to limited access to these tissues in humans, 
the function of these tissue-resident human ILCs in healthy and 
disease statuses has not been well characterized.
ILC3s are most intensively investigated due to their crucial 
role in gut immunity and inflammation. For example, gut-resi-
dent NKp44+ ILC3s can produce IL-22 that signals to epithelial 
cells to promote their proliferation (7). These ILC3s can also pro-
duce B cell–activating factors to support survival and expansion 
of mature B cells (18) and the chemokine CCL20 to direct the 
migration of T lymphocytes, B lymphocytes, and ILCs into the 
gut (19). Gut-resident NKp44– ILC3 cells express MHC class II 
antigens and can present microbial antigens to gut CD4+ T cells 
and inactivate gut commensal bacteria–specific T cell responses 
(20). Recently, ILC3s have also been reported to exist in the 
human spleen, where they interact with stromal cells for sur-
vival signals and enhance Ab production by innate-like B cells 
(17). Although these studies show that ILC3s can directly induce 
the proliferation and production of antiinflammatory cytokines 
and antimicrobial peptides of epithelial cells, it has not been 
addressed which immunological factors influence their survival 
in human diseases in vivo.
The regulation and role of ILC3s in HIV-1 infection, in par-
ticular, are poorly understood. It is reported that SIV infection 
results in a persistent loss of IL-17–producing ILCs, especially 
in the jejunum (21). Another report has indicated that NKp44+ 
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we found that serum LPS and sCD14 levels were significantly 
elevated and negatively correlated with percentages of ILC3 in 
peripheral blood (Figure 1C).
Development of functional human ILC3 cells in humanized 
mice. The characteristics and relevant role of ILC3s in HIV-1 
infection and pathogenesis are poorly understood, partially 
due to the lack of a robust model. Immunodeficient mice such 
as NOD-Rag2–/– Il12rg–/– (NRG) mice transplanted with human 
CD34+ hematopoietic stem cells can reconstitute all major 
human myeloid and lymphoid immune subsets. These human-
ized mice provide a valuable platform for studying the interac-
tion of human tropic viruses with the human immune system 
in vivo. HIV-1 can infect and replicate efficiently in vivo in 
humanized mice (26). More importantly, these mice mount spe-
cific human immune responses to HIV-1 infection and develop 
immunopathology similar to that of HIV-1–infected patients, 
which makes humanized mice a highly relevant model for 
studying mechanisms of HIV-1 immunopathogenesis and for 
developing immune-based therapies (27).
We thus took advantage of the well-developed human-
ized mouse model to investigate the function and role of ILC3 
in HIV-1 pathogenesis (28–31). By gating on live human CD45+ 
cells (hCD45+Y7–mCD45–) with a lymphoid morphology that 
was negative for common blood lineage markers (Lineage−) for 
hematopoietic precursors (CD34), B cells (CD19 and CD20), 
T cells (CD3), NK cells (CD16), and myeloid and plasmacy-
toid cells (CD14, CD11c and CD123), we identified human 
ILC3s in humanized NOD-Rag1–/– Il2rg–/– (NRG-hu) mice as 
hCD45+Lin–CD127+CD117+ cells. We analyzed both NKp44− 
ILC3s (NCR− ILC3s) and NKp44+ ILC3s (NCR+ ILC3s) (Supple-
mental Figure 2). We found that ILC3s were efficiently devel-
oped in all lymphoid organs of humanized mice including 
spleen, mesenteric lymph node (mLN), peripheral lymph node 
(pLN), BM, and peripheral blood lymphocytes (PBL) (Figure 
2A). Further analysis indicated that ILC3 subsets were prefer-
entially enriched in mLN and spleen (Figure 2B). These ILC3s 
showed phenotypic similarity to previously reported human 
splenic and mucosal ILC3s (7, 17, 19). They expressed the ILC3-
specific transcription factor RORγt, the NK cell–related mole-
cules CD56, CD161, NKp44, and NKp46, the chemokine CCL20 
receptor CCR6, IL-1R1, and the activation marker CD69 as well 
as CD45RA, but did not express the ILC1-specific transcription-
al factor T-bet, the integrin CD103, the NK-associated marker 
CD94, and CD4, CD8, CD25, or CD38 (Figure 2C). Function-
ally, these ILC3s were able to produce IL-17a, IL-22, IFN-γ, and 
IL-13 in response to PMA plus ionomycin (Figure 2D), with pref-
erential production of IL-17a and IL-22 (Figure 2E). In addition, 
these ILC3s from humanized mice also produced IL-17a and 
IL-22 in response to IL-23 and IL-1β stimulation at levels com-
parable to those of ILC3s from human peripheral blood (Supple-
mental Figure 3). Thus, human ILC3s with normal phenotype, 
frequency, and function are developed in the lymphoid organs 
of NRG-hu HSC mice.
HIV-1 infection leads to the activation of ILC3s in NRG-hu mice 
in vivo. As in human patients, HIV-1 infection in humanized 
mice also leads to systemic immune activation and disease pro-
gression (32). We tested to determine whether ILC3s were also 
ILC3s are rapidly depleted in the intestinal mucosa during acute 
SIV infection (22). In human patients chronically infected with 
HIV-1, reduction of ILC subsets has also been documented (23). 
However, how HIV-1 infection leads to ILC3 depletion in vivo is 
poorly understood. We report here that functional human ILC3s 
were developed in lymphoid organs of humanized mice, but 
were depleted by persistent HIV-1 infection in vivo, as in chronic 
HIV-1–infected patients. Interestingly, HIV-1 infection upregu-
lated CD95 expression on ILC3s via plasmacytoid dendritic cells 
(pDCs) and a type I IFN–dependent (IFN-I–dependent) mecha-
nism and sensitized them to undergo CD95/FasL-mediated 
apoptosis. The depletion of pDCs or blockade of the IFN-I or 
CD95/FasL pathway prevented HIV-1–induced ILC3 depletion in 
vivo and in vitro, respectively. Our findings suggest that modu-
lating pDC/IFN-I and CD95/FasL to rescue ILC3s will likely be 
of value in preventing or treating HIV-1 diseases.
Results
Depletion of human ILC3s in patients with chronic HIV-1 infec-
tion is correlated with HIV-1 disease progression. We measured the 
peripheral ILC3 frequency in HIV-1–infected antiretroviral treat-
ment–naive (ART-naive) patients and healthy control (HC) sub-
jects. Peripheral blood contained lineage–CD127+CD117+ ILC3 
subsets in all enrolled subjects (Figure 1A). Importantly, the 
peripheral ILC3s were significantly decreased in HIV-1–infected 
patients, in particular, in patients with CD4+ T cell counts of 
less than 400 cells/μl who displayed more severe reduction of 
ILC3 frequency as compared with that in HC subjects and HIV-
1–infected patients with CD4+ T cell counts of more than 400 
cells/μl (Figure 1, A and B). Correlation analysis indicated that 
peripheral ILC3 percentages were negatively correlated with 
plasma HIV-1 viremia in these HIV-1–infected highly active 
antiretroviral therapy–naive (HAART-naive) subjects (Figure 
1C). These data indicate that the decline of peripheral ILC3s is 
correlated with disease progression in HIV-1–infected patients.
As ILC3s are present in mucosal tissues (6), we stained colon 
tissues from uninfected and HIV-1–infected patients for CD3 
and IL-17 or IL-22. We found that CD3+IL-17+/CD3+IL-22+ cells 
(generally defined as Th17 cells) and CD3–IL-17+/CD3–IL-22+ 
(probably ILC3) cells were both present in the mucosa of 
colon tissue (Figure 1D and Supplemental Figure 1; supple-
mental material available online with this article; doi:10.1172/
JCI82124DS1). Double-staining immunohistochemistry further 
identified the presence of both CD3+IL-17+/CD3+IL-22+ Th17 
cells and CD3–IL-17+/CD3–IL-22+ ILC3 cells in colon tissues 
from HIV-negative subjects (Figure 1E). After HIV-1 infection, 
total IL-17+ and IL-22+ cells (but not total CD3+ T cells) were sig-
nificantly depleted (Figure 1F), consistent with previous reports 
documenting the loss of Th17 cells in chronic SIV infection (24, 
25). Furthermore, these depleted IL-17+ and IL-22+ cells in HIV-
1–infected colons included not only CD3+IL-17+/CD3+IL-22+ 
Th17 cells, but also CD3–IL-17+/CD3–IL-22+ ILC3 cells (Figure 
1F). These data suggest that ILC3s, as well as Th17 cells, are 
depleted in the colon mucosa in HIV-1–infected subjects. As 
ILC3s are critically involved in the maintenance of the gut barri-
er function, we further looked at the LPS and sCD14 levels in the 
serum of HIV-1–infected HAART-naive patients. Impressively, 
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Figure 1. HIV-1 disease progression is associated with depletion of ILC3 cells in human patients. (A) Representative FACS plots show the proportion 
of ILC3s in peripheral blood of enrolled human subjects. The numbers indicate the percentages of ILC3s (CD127+CD117+ cells) within CD45+Lin– cells. 
VL, viral load. (B) Summary data of percentages of ILC3s in CD45+Lin– cells in HC subjects (n = 20), HIV-1–infected patients with CD4+ T cell counts 
of more than 400 cells/μl (n = 18), and those with CD4+ T cell counts of fewer than 400 cells/μl (n = 37). Overall, P = 0.003, 1-way ANOVA; P values 
shown in the figures are based on Tukey’s post-hoc test. (C) Correlation analysis between the percentages of ILC3s and plasma HIV-1 loads, LPS activ-
ity, and sCD14 levels (Spearman rank correlation test). r, correlation coefficient. (D) Costaining of CD3 with IL-17 or IL-22 in colon mucosal specimens 
from HIV-1–negative and HIV-1–positive subjects by confocal microscopy. Original magnification, ×400. Representative staining shows CD3+ (green), 
IL-17+, and IL-22+ (red) cells. DAPI was used to counterstain nuclear DNA (blue). The insert shows CD3+IL-17+ or CD3+IL-22+ Th17 cells and CD3–IL-17+ 
or CD3–IL-22+ ILC3s. (E) Immunohistochemical costaining for mucosal CD3+IL-17+ Th17 cells (black arrows) and CD3–IL-17+ ILC3 cells (yellow arrows) in 
colons of HIV-1–uninfected and HIV-1–infected subjects. hpf, ×400.(F) Numbers of colon mucosal CD3+ T cells, Th17 cells, and ILC3 cells are calculated 
in various subjects (2-tailed unpaired Student’s t test).
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both NCR+ and NCR– ILC3 subsets 
were similarly depleted (Supplemen-
tal Figure 4). When HIV-1 replication 
was effectively suppressed by cART, 
ILC3s were completely recovered in 
HIV-1–infected NRG-hu mice (Fig-
ure 4, A and B).
We further analyzed whether 
persistent HIV-1 infection affected 
the cytokine-producing activity of 
ILC3s in vivo (Figure 4C). Our data 
showed that ILC3s from HIV-1–
infected NRG-hu mice produced less IL-17a but comparable 
IL-22, IL-13, and IFN-γ in response to PMA plus ionomycin 
stimulation in vitro. When HIV-1 was suppressed by cART, the 
IL-17a production by ILC3s was significantly recovered (Figure 
4D). We concluded that ILC3s in NRG-hu mice were depleted 
and preferentially functionally impaired to produce IL-17a by 
HIV-1 infection, which can be recovered by cART.
The depletion of ILC3s by HIV-1 infection is dependent on pDCs 
and IFN-I activity. We recently reported that depletion of pDCs 
using the anti–blood dendritic cell antigen-2 (anti-BDCA2) Ab 
(15B) in NRG-hu mice led to elevated HIV-1 replication, but with 
reduced immunopathogenesis (28). In humanized mice with 
persistent HIV-1 infection, we detected high levels of plasma 
IFN-α, although pDC levels were reduced in the spleen (Figure 
5A). Consistent with our previous study, IFN-α induction was 
abrogated either by inhibiting HIV-1 replication with cART or 
by depleting pDC with the 15B mAb in persistently HIV-infect-
ed NRG-hu mice (Figure 5B) and was correlated with reduced 
immunopathogenesis (Figure 5, C–F), as indicated by the elevat-
activated by HIV-1 infection in humanized mice through detec-
tion of CD38 and CD69 expression on ILC3s in spleen and mLN 
of NRG-hu mice persistently infected with HIV-1. A significant 
elevation of both CD69 and CD38 expression was induced on 
these tissue-resident ILC3s by persistent HIV-1 infection, while 
combined ART (cART) significantly decreased the expression of 
these 2 activation markers on ILC3s (Figure 3, A and B). Interest-
ingly, the activation level of tissue-resident ILC3s was positively 
correlated with CD8+ T cell activation indicated by CD38 and 
HLA-DR expression (Figure 3C). HIV-1 infection thus poten-
tially activated human tissue–resident ILC3s in NRG-hu mice, 
and their activation was positively correlated with systematic 
immune activation.
Persistent HIV-1 infection depletes ILC3s and preferentially 
impairs their activity to produce IL-17a in NRG-hu mice in vivo. We 
next investigated the effect of persistent HIV-1 infection on tis-
sue-resident ILC3s in NRG-hu mice and found that HIV-1 infec-
tion significantly reduced both percentages and numbers of 
ILC3s in the spleen, mLN, and BM (Figure 4, A and B). Notably, 
Figure 2. Development of functional 
ILC3s in lymphoid organs in NRG-hu 
mice. (A) Representative FACS plots 
show the distribution of ILC3s (human 
CD45+Lin–CD127+CD117+ cells) in various 
lymphoid organs of NRG-hu mice. Num-
bers indicate the percentages of ILC3s 
within hCD45+Lin– cells. (B) Summary 
data of relative frequency of ILC3s among 
hCD45+Lin– cells. Spleen, n = 56; mLN,  
n = 11; pLN, n = 9; BM, n = 20; PBL,  
n = 9. (C) Expression on splenic 
hCD45+Lin−CD127+CD117+ ILC3s (black 
lines) of RORγt, T-bet, CCR6, CD11a,  
IL-1R1, CD161, CD56, NKp46, CD94, NKp44, 
HLA-DR, CD103, CD69, CD38, CD25, 
CD45RA, CD4, and CD8, assessed by flow 
cytometry (n = 4). Gray shaded curves 
represent isotype control. (D) Represen-
tative FACS plots show the production of 
IL-17a, IL-22, IFN-γ, and IL-13 by splenic 
ILC3s (human CD45+Lin–CD127+CD117+) 
from NRG-hu mice stimulated with PMA 
plus ionomycin for 4 hours. Numbers 
indicate percentages of cytokine-produc-
ing ILC3s. (E) Summary data of relative 
cytokine-producing ILC3s from mLN  
(n = 5), spleen (n = 7), and BM (n = 5).
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of tissue-resident ILC3s through inducing apoptosis in HIV-1–
infected NRG-hu mice.
Sustained IFN-I production by pDCs has been implicated as 
contributing to immunopathogenesis by chronic HIV-1 infection 
(33–36). We thus addressed whether IFN-I is responsible for HIV-
1–induced depletion of ILC3s. We incubated spleen cells from nor-
mal NRG-hu mice with the HIV-R3B/A-v1v2 virus, which is char-
acterized by high IFN-I induction activity (37), in the absence or 
presence of pDC-depleting Abs or anti–IFN-α/β receptor–blocking 
Abs. We found that HIV-1 infection significantly increased active 
caspase-3 expression (apoptosis) in human ILC3s, which was pre-
vented by depletion of pDCs using 15B conjugated with a toxin 
(15B-SAP) or blockade of the IFN-α/β pathway using anti–IFN-α/β 
receptor Abs (Figure 6, G and H). Consistently, HIV-1 infection 
also reduced the number of ILC3s in vitro, which was reversed by 
depletion of pDCs or blocking IFN-α/β receptors (Figure 6I). As 
pDCs were the major sources of IFN-I in response to HIV-1 infec-
tion (Supplemental Figure 7), we concluded that HIV-1–induced 
ILC3 apoptosis was mainly mediated by pDC-derived IFN-I.
HIV-1 infection induces CD95 expression and apoptosis of 
ILC3s through pDC/IFN-I–dependent mechanisms. We next 
ed human CD45+ cell counts and CD4+ and CD8+ T cell counts 
(Figure 5, D–F). Interestingly, the percentage of ILC3s was nega-
tively correlated with pDC levels in lymphoid organs of NRG-hu 
mice with persistent HIV-1 infection (Supplemental Figure 5).
The data above suggest that persistently activated pDCs 
may contribute to the depletion of ILC3s during HIV-1 infection. 
We thus tested the role of pDCs in the loss of ILC3 cells through 
depleting pDCs using the anti-BDCA2 Ab (15B) in NRG-hu mice 
with persistent HIV-1 infection as reported (28). We observed 
that pDC depletion with the 15B mAb significantly rescued 
splenic ILC3s (Figure 6, A and B) and restored their IL-17a and 
IL-22 production capacity in NRG-hu mice with persistent HIV-1 
infection (Figure 6, C and D). We next determined whether 
HIV-1 infection led to ILC3 cell death. We discovered that HIV-1 
infection induced ILC3 apoptosis (upregulation of active cas-
pase-3) and that pDC depletion significantly reduced the per-
centage of ILC3s expressing active caspase-3 in the spleen of 
NRG-hu mice with persistent HIV-1 infection (Figure 6, E and 
F). As a control, pDC depletion did not change the percentage of 
ILC3s in mock-infected humanized mice (Supplemental Figure 
6). These data suggest that pDCs were involved in the depletion 
Figure 3. Activation of tissue-resident ILC3s is associated with persistent HIV-1 infection and with systematic immune activation in NRG-hu mice. 
NRG-hu mice were infected with JR-CSF (10 ng p24/mouse, i.v.). After HIV-1 established persistent infection at 8 wpi, combined antiretroviral drugs 
(cART, PI + NNRTI, each 100 mg/kg) were administered for 4 to 6 weeks. The mice were then terminated, and cells were analyzed. (A) Representa-
tive FACS plots show expression of activation markers CD69 and HLA-DR on splenic ILC3s from NRG-hu mice. The numbers indicate percentages of 
ILC3-expressing CD69 or HLA-DR. (B) Summary data of CD69 and HLA-DR on ILC3s from spleen and mLN in mock (n = 9), HIV-1–infected (n = 9), and 
HIV-1–infected NRG-hu mice with cART (n = 4). Data are representative of 3 independent experiments with 1 to 3 donors. Overall, for percentages of 
ILC3s for spleen, P = 0.0004 (CD38); P = 0.0003 (CD69). Overall, for percentages of ILC3s from mLN, P = 0.0473 (CD38); and P = 0.0902 (CD69), 1-way 
ANOVA. *P < 0.05; **P < 0.01; ***P < 0.001, Tukey’s post-hoc test. (C) Correlation analysis between the percentages of CD8+ T cells expressing CD38 
and HLA-DR and the percentages of ILC3s expressing CD38 or CD69 (Pearson correlation test).
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examined the apoptosis pathway involved in ILC3 depletion that 
is induced by HIV-1 infection, pDC activation, and IFN-I. IFN-α 
has been reported to upregulate CD95 expression on human T 
cells in HIV-1–infected patients (38). We thus investigated the 
role of CD95-mediated apoptosis in the depletion of ILC3s dur-
ing HIV-1 infection. We found that expression of CD95 was 
upregulated on splenic ILC3s in NRG-hu mice with persistent 
HIV-1 infection. Importantly, we also detected similar upregu-
lation of CD95 on ILC3s isolated from peripheral blood and 
spleens of HIV-1–infected patients (Figure 7, A and B). We next 
addressed whether pDCs or IFN-I drives CD95 upregulation 
on ILC3s upon HIV-1 infection in vitro using spleen cells from 
humanized mice. Spleen cells from NRG-hu mice were treated 
with IFN-α or with HIV-1 in the absence or presence of pDC-
depleting 15B mAb conjugated with the SAP toxin (immune-
toxin 15B-sap) or the anti–IFN-α/β receptor Ab to block IFN-I 
Figure 4. Persistent HIV-1 infection in NRG-hu mice depletes ILC3s and preferentially impairs their activity in IL-17a production. NRG-hu mice were 
treated as described in the Figure 3 legend. (A) Representative FACS plots show the depletion and cART rescue of ILC3s in mLN, spleen, and BM of 
NRG-hu mice with persistent HIV-1 infection. Numbers indicate percentages of ILC3s within hCD45+Lin– cells. (B) Summary data of the percentages of 
ILC3s from mLN, spleen, and BM in mock (n = 12), HIV-1–infected (n = 6), and HIV-1–infected with cART-treated NRG-hu mice (n = 8). Overall, for ILC3 
percentages, P = 0.0237 (mLN); P = 0.0088 (spleen); P = 0.0178 (BM). For ILC3 cell counts, P = 0.0339 (mLN); P = 0.0024 (spleen); P = 0.0404 (BM), 
1-way ANOVA. *P < 0.05; **P < 0.01, Tukey’s post-hoc test. Data are representative of 3 independent experiments with 3 to 4 donors. (C) Representa-
tive FACS plots show IL-17a production by splenic ILC3s stimulated with PMA plus ionomycin for 4 hours. Numbers indicate percentages of cytokine-
producing ILC3s. (D) Summary data of cytokine-producing ILC3s from spleens of mock-infected (n = 7), HIV-1–infected (n = 5), and HIV-1–infected with 
cART-treated NRG-hu mice (n = 4). Data are representative of 2 independent experiments with 3 to 4 donors. Overall, for percentages of ILC3s from 
spleen, P = 0.0051 (IL-17); P = 0.0484 (IL-22); P = 0.0921 (IFN-γ); P = 0.7237 (IL-13), 1-way ANOVA. *P < 0.05; **P < 0.01, Tukey’s post-hoc test.
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activity. IFN-α treatment significantly upregulated CD95 
expression on splenic ILC3s. Importantly, HIV-1 also induced 
a 3-fold upregulation of CD95 expression on ILC3s in spleno-
cytes cultured in vitro (Figure 7C). The upregulation of CD95 
was at least partially dependent on pDCs or IFN-I, as depletion 
of pDCs or blockade of the IFN-α/β pathway partially prevented 
CD95 upregulation on ILC3s (Figure 7C).
We then infected spleen cells from NRG-hu mice ex vivo 
with HIV-1 for 72 hours, followed by 12-hour stimulation with 
immobilized anti-CD95 Abs. We found that HIV-1–exposed 
ILC3s showed higher levels of active caspase-3 expression after 
anti-CD95 treatment (Figure 7D). Importantly, this increase 
was inhibited by blocking the IFN-α/β pathway using anti–IFN-
α/β receptor Abs (Figure 7D), suggesting that pDC-derived 
IFN-I and the CD95/FasL pathway contribute to the depletion 
of ILC3s during HIV-1 infection. Similarly, ILC3s from HIV-1–
infected patients also displayed higher levels of active caspase-3 
expression than ILC3s from HC people after in vitro anti-CD95 
Ab treatment (Figure 7E). In addition, the blockade of the 
CD95/FasL pathway using anti-FasL Abs or of the apoptotic 
pathway using the caspase inhibitor Zvad significantly rescued 
ILC3s by decreasing apoptosis and by increasing cell numbers 
ex vivo (Figure 7, F–H). Based on these findings, we postulate 
that activation of pDCs by HIV-1 infection induces the produc-
tion of type I IFNs, which upregulate CD95 expression and sen-
sitize ILC3s to CD95/FasL-mediated apoptosis (Figure 7I).
Discussion
It has been reported that 
acute and chronic HIV-1/SIV 
infection potentially induc-
es the rapid loss of muco-
sal IL-17/IL-22–producing 
T cells and ILC3s (21–23), 
which may both contrib-
ute to the loss of intestinal 
epithelial mucosal integ-
rity (24, 39, 40). However, 
the mechanism underlying 
HIV-1–induced depletion 
of ILC3s is poorly defined. 
Using a humanized mouse 
model of HIV-1 pathogen-
esis, we report here that 
persistent HIV-1 infection 
depletes functional human 
ILC3s in patients and in 
humanized mice in vivo 
through pDC activation, 
IFN-I induction, and upreg-
ulation of CD95 expres-
sion on ILC3s, with great 
potential significance to the 
pathogenesis and therapy of 
this disease.
The role of ILC3s, espe-
cially tissue-resident ILC3s, 
during HIV-1 disease pro-
gression is poorly defined due to a lack of relevant models and 
limited access to the tissues in humans. Humanized mouse mod-
els have been used widely to investigate the mechanisms of HIV-
1 immunopathogenesis, including functionally defining the role 
of regulatory T cells (41), pDCs (30), and other cells (29) in acute 
and chronic HIV-1 infection. In the present study, we found that 
human ILC3 subsets were functionally developed in all lymphoid 
organs in NRG-hu mice and preferentially resided in the spleen 
and mLN. They displayed molecular markers (42, 43), functions 
(4), and tissue distribution similar to that seen in humans (7, 
17, 19). However, due to the poor gut-associated lymphoid tis-
sue (GALT) development in humanized mice with the common 
γ-chain mutation, the NRG-hu mouse model has an intrinsic lim-
itation for the study of human immune cells in GALT. Nonethe-
less, the humanized mouse provides a highly relevant and robust 
model for studying the development and function of human 
ILC3s and defining their roles in human diseases in vivo.
Using the humanized mouse model, we investigated the 
effect of persistent HIV-1 infection on human ILC3s in human 
lymphoid tissues. Our study provides what we believe is the 
first evidence that HIV-1 infection leads to activation, severe 
depletion, and preferential impairment of IL-17a production of 
tissue-resident ILC3s in the spleen, BM, and mLN in humanized 
mice as well as in the blood and colon mucosa of HIV-1–infected 
patients. Efficient suppression of HIV-1 by cART in humanized 
mice reduced ILC3 activation and rescued ILC3s both in num-
Figure 5. Depletion of pDCs increases HIV-1 replication, but reduces HIV-1–induced immunopathogenesis. Human-
ized mice were infected with HIV-JRCSF for 8 weeks and were subsequently treated with 15B or cART twice every week 
for 6 weeks and terminated at 14 wpi (mock, n = 6; JR-CSF, n = 6; JR-CSF+cART, n = 8; JR-CSF+15B, n = 6). Splenic pDC 
percentages (A), plasma IFN-α (B), and HIV-1 genome RNA levels (C), and splenic hCD45+ cell counts (D) and CD4+ (E) 
and CD8+ T cell counts (F) were analyzed in 4 groups of mice. Data are representative of 3 independent experiments 
with 3 to 4 donors. Overall, for pDC percentages, P = 0.0053; P < 0.0001 (plasma IFN-α); P < 0.0001 (plasma HIV-1 
load); P = 0.0009 (splenic hCD45+ cell counts); P < 0.0001 (CD4+ T cell counts); and P = 0.0022 (CD8+ T cell counts), 
1-way ANOVA. *P < 0.05; **P < 0.01; ***P < 0.001, Tukey’s post-hoc test.
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ber and in function. IL-17 and 
IL-22 are important for protec-
tion against mucosal bacterial 
infections and for maintenance 
of the mucosal barrier by pro-
motion of intestinal epithelial 
integrity (24, 39, 40). Multiple 
immune cells, including Th17 
cells (44), NKp44+ NK22 cells 
(7, 22, 25), and CD3–CD8hi sub-
sets (21), could produce these 2 
cytokines. The loss of these cells 
in chronic HIV-1/SIV infection 
has been correlated with break-
down of intestinal mucosal 
integrity, resulting in microbial 
translocation, chronic immune 
activation, and disease progres-
sion (21, 22, 24, 25, 45–47). The 
present study extends the notion 
that the numeral and functional 
loss of the tissue-resident ILC3s 
also contribute to the pathogen-
esis induced by persistent HIV-1 
infection. This study, therefore, 
identifies ILC3s as an impor-
tant target for therapies aimed 
at facilitating human immune 
reconstitution. Future studies 
need to address the functional 
role of ILC3s in lymphoid tis-
sue destruction, the fibrosis of 
lymph organs, and immune acti-
vation during persistent HIV-1 
infection (48).
The exact mechanism under-
lying the depletion of ILC3s dur-
ing HIV-1 infection remains 
unclear. We have recently 
reported that pDCs play a patho-
genic role in HIV-1 infection 
and pathogenesis (28). We also 
demonstrated the role of human 
pDCs in HIV-1–induced deple-
tion of ILC3s. We discovered 
that pDCs (and IFN-I) contrib-
uted to the loss of ILC3s during 
chronic HIV-1 infection. First, 
depletion of pDCs in NRG-hu 
mice persistently infected with 
HIV-1 rescued human ILC3s 
in lymphoid organs. Second, 
HIV-1–infected splenocytes from 
humanized mice ex vivo also 
led to ILC3 death and deple-
tion. As in humanized mice in 
vivo, either depletion of pDCs or 
Figure 6. HIV-1 infection leads to ILC3 depletion via pDC- and IFN-I–dependent mechanisms. (A and B) 
Representative FACS plots (A) and summary data (B) show splenic ILC3 percentages within CD45+Lin– cells 
in mock (n = 9), HIV-1–infected (n = 7), and HIV-1–infected/pDC-depleted (n = 9) NRG-hu mice. Data are 
representative of 3 independent experiments with 3 donors. Overall, for ILC3 percentages, P < 0.0001, 1-way 
ANOVA.*P < 0.05; **P < 0.01, Tukey’s post-hoc test. (C and D) Summary data of IL-17a–producing (C) and 
IL-22–producing (D) ILC3s from spleens of mock (n = 4), HIV-1 (n = 4), and HIV-1+15B (n = 5) mice. Data are 
representative of 2 independent experiments with 2 donors. Overall, for ILC3 percentages, P = 0.0039  
(IL-17a); P = 0.0031 (IL-22), 1-way ANOVA. *P < 0.05; **P < 0.01, Tukey’s post-hoc test. (E and F) Represen-
tative histograms (E) and summary data (F) show the percentages of active caspase-3–expressing splenic 
ILC3s within hCD45+Lin– cells in mock (n = 4), HIV-1–infected (n = 4), and HIV-1–infected/pDC depletion  
(n = 5) NRG-hu mice. Overall, P = 0.0374, 1-way ANOVA; *P < 0.05, Tukey’s post-hoc test. Data are represen-
tative of 3 independent experiments with 1 to 3 donors. (G–I) Representative histograms (G) and summary 
data show the percentages of active caspase-3–expressing ILC3 (H) and total live ILC3 cell counts (I) relative 
to mock. Spleen cells from NRG-hu mice were incubated for 72 hours ex vivo alone (mock) or infected with 
HIV-1 in the presence of no Ab (medium), IgG, 15B-sap immunotoxin (8 ng/ml), or anti–IFN-α/β receptor  
(10 μg/ml) Abs. The percentage of ILC3s expressing active caspase-3 was measured. Data are representa-
tive of 2 independent experiments with 2 donors. *P < 0.05; **P < 0.01, compared with mock. #P < 0.05, 
compared with HIV+IgG (Tukey’s post-hoc test).
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Figure 7. HIV-1 infection upregulates CD95 on ILC3s through pDC/IFN-I–dependent mechanisms. (A and B) Representative histograms (A) and sum-
mary data (B) indicate percentages of CD95-expressing ILC3s in spleens from mock (n = 4) and HIV-1–infected (n = 6) NRG-hu mice and HC  
(n = 10) and HIV-1–infected patients (n = 12). **P < 0.01; ***P < 0.001 (unpaired t test). Data are representative of 2 independent experiments with 
humanized mice from 2 to 3 donor tissues. (C) Representative histograms show percentages of CD95-expressing ILC3s incubated ex vivo for 72 hours 
alone (gray), with IFN-α (blue line), with HIV-1 alone (red line), or with HIV-1 plus pDC immunotoxin 15B-sap (black line) or anti–IFN-α/β receptor Abs 
(shade). Data are representative of 3 independent experiments with 2 donors. (D) HIV-1 infection increases the sensitivity of ILC3s to CD95/FasL-
induced apoptosis via pDC-produced IFN-I. Spleen cells from NRG-hu mice were preincubated with mock, HIV-1 alone, or HIV-1 in the presence of 
anti–IFN-α/β receptor Abs (10 μg/ml) for 72 hours and then stimulated with plate-coated anti-Fas Abs (5 μg/ml) for 12 hours. *P < 0.05;  
**P < 0.01, ANOVA with Tukey’s post-hoc test. (E) IFN-I increases the sensitivity of T cells to CD95/Fas-induced death in HIV-1–infected individuals. 
PBMCs from HC (n = 5) and HIV-1–infected subjects (n = 5) were stimulated with plate-bound anti-Fas Ab for 6 hours. Cells were then harvested and 
stained for active caspase-3. **P < 0.01; ***P < 0.001, unpaired t test. (F–H) Representative histograms (F) and summary data show percentages of 
active caspase-3–expressing splenic ILC3s (G) and live ILC3 cell counts (H) relative to mock. Spleen cells from NRG-hu mice were incubated 72 hours 
ex vivo alone (mock) or with HIV-1 in the presence of no Ab (medium), isotype control Ab (IgG), anti-FasL Ab (10 μg/ml), or Zvad (50 μM). The per-
centage of ILC3s expressing active caspase-3 was measured.*P < 0.05; **P < 0.01, compared with mock; #P < 0.05, compared with HIV+IgG (Tukey’s 
post-hoc test). Data are representative of 2 independent experiments with 2 donors. (I) A model of HIV-1–induced ILC3 depletion. Activation of pDCs 
by HIV-1 infection expresses IFN-I, which upregulates CD95 expression and sensitizes tissue-resident ILC3s to CD95/FasL-mediated apoptosis.
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Methods
Patients and human samples. Fifty-five HIV-1–infected HAART-naive 
individuals were enrolled in our study. Based on their CD4+ T cell 
counts, they were divided into 2 groups: a cohort of 18 subjects with 
CD4+ T cell counts of more than 400 cells/μl and 37 subjects with 
CD4+ T cell counts of less than 400 cells/μl (Supplemental Table 1). 
The majority of these individuals had been infected with HIV-1 via 
sexual transmission, while a few subjects were paid blood donors. 
Twenty uninfected subjects were employed as HCs. Peripheral blood 
mononuclear cells (PBMCs) were isolated by Ficoll-Hypaque density 
gradient centrifugation from heparinized blood of enrolled subjects. 
Paraffin-embedded colon mucosa tissues were available from 7 HIV-
1–infected patients and from 9 HIV-negative donors who underwent 
colon cancer resection.
Construction of humanized mice. We constructed NRG-hu mice 
similarly to what was previously reported (31). Briefly, human CD34+ 
cells were isolated from 16- to 20-week-old fetal liver tissues. Tis-
sues were digested with liver digest medium (Invitrogen). The sus-
pension was filtered through a 70-μm cell strainer (BD Falcon) and 
was centrifuged for 5 minutes to isolate mononuclear cells by Ficoll. 
After selection with the CD34+ magnetic-activated cell sorting 
(MACS) kit (Human CD34 MicroBead Kit, Miltenyi Biotec), CD34+ 
hematopoietic stem cells were injected into the livers of irradiated 
(3 Gy) 2- to 6-day-old NRG mice (0.5 × 106/mouse). More than 95% 
of the humanized mice were stably reconstituted with human leu-
kocytes in the blood (60%–90% at 12–14 weeks). Each cohort had 
similar levels of engraftment. All mice were housed at the University 
of North Carolina at Chapel Hill.
HIV-1 virus stocks and infection of humanized mice. An R5 tropic 
strain of HIV-1, JR-CSF, was used for persistent HIV-1 infection. Virus-
es were generated by transfection of 293T cells. Humanized mice with 
stable human leukocyte reconstitution were infected with JR-CSF at a 
dose of 10 ng p24/mouse, through intraorbital injection. Humanized 
mice infected with mock-transfected 293T cell culture supernatant 
were used as control groups. For the humanized mice with persistent 
HIV-1 infection, antiviral drugs (PI and NNRTI, each 100 mg/kg body 
weight) were given orally to some mice twice every week for 4 to 6 
weeks. Viral genomic RNA in plasma was measured by real-time PCR 
(ABI Applied Biosystem). An X4 and R5 dual-tropic strain of HIV-1, 
R3B/Av1v2 (37), was used for in vitro exposure.
Depletion of human pDCs in NRG-hu mice. A mAB specific to BDCA2, 
clone 15B, was used to deplete pDCs in humanized mice through i.p. 
injection (4 mg/kg) as previously reported, with minor modifications 
(28). In brief, for mice with persistent HIV-1 infection, 15B was applied 
to mice at 8 weeks post infection (wpi) by injecting twice every week for 
6 weeks, followed by termination. 15B mAb conjugated with the toxin 
sap (15B-sap, 8 ng/ml) was used to deplete pDCs in vitro.
Tissue processing. Total leukocytes were isolated from PBL, pLN, 
mLN, spleen, and BM as previously described (28, 30, 41). Lymphoid 
tissues, including red blood cells, were lysed with ACK buffer, and the 
leukocytes were stained and fixed with 1% formaldehyde before FACS 
analysis. Total cell number was quantified by Guava Easycytes with 
Guava Express software (Guava).
Flow cytometry. Flurochrome-conjugated Abs or regents from Bio-
Legend, BD Biosciences, eBioscience, and R&D Systems were used in 
mouse experiments in the study (Supplemental Table 2). For human-
ized mice, live human leukocytes (Y7–mCD45–hCD45+) were analyzed 
blockade of the IFN-I pathway also efficiently rescued ILC3s from 
HIV-1–induced apoptosis. Therefore, it is likely that persistent 
activation of pDCs by HIV-1 infection induces IFN-I expression, 
which contributes to ILC3 depletion. Interestingly, a recent report 
suggests that chronic virus infection increases epithelial turnover 
in multiple tissues through IFN-I–dependent mechanisms (49). 
We thus postulate that sustained pDC activation and IFN-I pro-
duction during persistent HIV-1 infection may possibly impair 
the integrity of the intestinal mucosal barrier by depleting tissue-
resident ILC3 cells. It will be of importance to address whether 
and how pDCs may contribute to HIV-1 pathogenesis in mucosal 
tissues such as the gut.
We also addressed the question of how pDCs and IFN-I con-
tribute to ILC3 apoptosis during chronic HIV-1 infection. Our 
data indicate that HIV-1 infection or IFN-I markedly enhances 
CD95 expression on ILC3s, thus sensitizing ILC3s to undergo-
ing CD95/FasL-mediated apoptosis. Blocking CD95/FasL sig-
naling with anti-FasL mAb, as pDC depletion or IFN-I–signaling 
blockade, also prevented ILC3 depletion in response to HIV-1 
infection. It is interesting that CD4+ T cells from HIV-1–infected 
patients also show increased susceptibility to CD95/FasL-medi-
ated apoptosis (50). Therefore, persistent production of IFN-I by 
pDCs during chronic HIV-1 infection (51–53) may not only com-
promise CD4+ T cell survival, but may also deplete tissue-resi-
dent ILC3s. This study thus reveals the pDC/IFN-I and CD95/
FasL axis in mediating HIV-1–induced depletion of human 
ILC3s, although other death pathways may also be involved in 
ILC3 depletion (54). Recent reports have also highlighted that 
microbial and dietary signals can significantly influence intesti-
nal ILC3s (55, 56).
Finally, the depletion of ILC3s may serve as a unique marker 
of disease progression of chronic HIV-1 infection. This study has 
revealed a marked association of the depletion of ILC3s with 
persistent HIV-1 replication, systematic immune hyperactiva-
tion, and defective gut barrier function. We also demonstrated 
that chronic HIV-1 infection may upregulate CD95 expression 
on ILC3s through pDC-derived IFNs and subsequently induce 
CD95/FasL-mediated apoptosis of ILC3s. Additional analyses 
are also required to identify the regulatory pathways that impair 
IL-17a production by ILC3s in the lymphoid organs. However, 
it should be noted that depletion of pDCs is a two-edged sword 
for patients. It helps immune reconstitution, but increases HIV 
replication. The potential benefit of pDC depletion would be to 
those HIV-1–infected “immune nonresponder” patients, whose 
HIV is efficiently suppressed by cART but who still exhibit 
chronic immune activation and gut barrier impairment and who 
lack full immune reconstitution.
Taking these data together, we report that chronic HIV-1 
infection depletes human ILC3s in lymphoid organs in vivo 
through pDC activation and/or induction of IFN-I, which sen-
sitized ILC3s to undergo CD95/FasL-mediated apoptosis. Our 
findings suggest that modulating pDC/IFN-I and CD95/FasL 
to manipulate ILC3s will likely provide an avenue to prevent 
or treat HIV-1 diseases. The humanized mouse model will also 
serve as a valuable model to develop therapeutics that target 
pDC/IFN-I and restore functions of human ILC3s in HIV-1–
infected patients.
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tions according to our protocols (44). Sections were incubated with 
primary mAbs, including anti–CD3 and anti–IL-17a (AF1086, R&D) 
or anti–IL-22 (Ab18499, Abcam). The avidin-biotin-peroxidase sys-
tem with 3-amino-9-ethyl-carbazole (AEC) (red color) or vector 
blue (blue color) as substrates was used to perform double staining. 
CD3–IL-17a+ cells or CD3–IL-22+ cells in colon mucosa were identi-
fied as ILC3s, while CD3+IL-17a+ cells or CD3+IL-22+ cells were iden-
tified as Th17 cells. The absolute number of ILC3 and Th17 cells 
was independently counted by 2 pathologists from 3 representative 
high-power fields (hpf, ×400) relative to the area with the greatest 
inflammatory infiltrate. In addition, immunofluorescence tristain-
ing was performed as previously reported, with minor modifications 
(57). Briefly, the tissues were incubated overnight with primary Abs 
(anti-human CD3, anti-human IL-17, and anti-human IL-22, all dilut-
ed 1:10) followed by secondary Abs (rabbit anti-mouse FITC-conju-
gated IgG Ab, rhodamine-conjugated goat anti-mouse IgG Ab, and 
DAPI for nucleic acid staining) for 45 minutes at room temperature. 
Confocal imaging was used to scan the slides.
Statistics. Data were analyzed using GraphPad Prism software 
version 5.0. Data represent mean ± SEM. For 2 groups, a 2-tailed, 
unpaired Student’s t test was used. For 3 or more groups, 1-way ANOVA 
was used for primary comparisons among different groups and giv-
en an overall P value. The secondary comparisons between any 2 
different cohorts of mice or patients were performed using Tukey’s 
post-hoc test. Correlations between variables were evaluated using 
the Pearson correlation test for data from mice and the Spearman 
rank correlation test for data from humans. Results were considered 
significant at P < 0.05.
Study approval. The study protocol for humans was approved by 
the Ethics Committee of Beijing 302 Hospital, and written informed 
consent was obtained from each subject. All animals studies were 
approved by the University of North Carolina Institutional Animal 
Care and Use Committee (IACUC).
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for ILC3 subsets and other cell subsets by the CyAn FACS machine 
(Dako, Beckman Coulter). Live/dead fixable violet dead cell dye (LD7) 
was purchased from Molecular Probes. Data were analyzed by Summit 
software. For human PBMCs, CD45+ cells were analyzed for pheno-
typic expression by FACSVerse and data were further analyzed with 
FlowJo software (TreeStar). Cytokines including IL-2, IL-12, IL-18, 
IL-1β, and IL-23 were purchased from PeproTech, and IFN-α was from 
Roche Pharmaceuticals.
For surface marker staining, leukocytes were incubated with Abs 
on ice for 30 minutes and then washed and fixed for further analysis. 
For the staining of HIV-1 gag p24, transcriptional factors, and apoptot-
ic marker active caspase-3, cells were stained with surface marker first 
and then permeabilized using a Cytofix/Cytoperm kit (BD Bioscience) 
and stained for intracellular protein.
For intracellular cytokine detection, freshly isolated cells were 
stimulated for 4 hours with PMA (50 ng/ml; Sigma-Aldrich) and iono-
mycin (1 μM; Merck) in the presence of BFA (1 μM) for culture. Alter-
natively, the cells were incubated with IL-12 (20 ng/ml) plus IL-18 
(20 ng/ml) or IL-1β (20 ng/ml) plus IL-23 (20 ng/ml) for 12 hours 
followed by GolgiStop (BD) for an additional 6 hours. The cells were 
then collected for surface marker staining, followed by cell permeabi-
lization and intracellular cytokine staining.
HIV-1 infection in vitro. R3B/Av1v2 stocks were used in the 
experiments. Splenic cells from NRG-hu mice were pretreated with 
an anti–IFN-α/β receptor Ab (10 μg/ml, Millipore), anti–FasL Ab 
(NOK-1, 10 μg/ml, BD Biosciences — Pharmingen), or an isotype 
control, Zvad (50 μM, R&D systems) or 15B-sap (8 ng/ml), for 30 
minutes on ice. The infectious HIV-R3B/A or mock stock was then 
added for 2-hour incubation at 37°C. Then the cells were incubated 
in complete RPMI 1640 medium at a density of 2 × 106 cells/ml in the 
presence of IL-1β (10 ng/ml), IL-23 (10 ng/ml), and IL-2 (50 IU/ml) 
for an additional 3 days. Percentages of apoptotic ILC3s (active 
caspase-3–expressing ILC3s) were determined by flow cytometry 
as described above. Total live cell number was quantified by Guava 
Easycyte with Guava Express software.
Apoptosis induction assays. Splenic cells from NRG-hu mice were 
pretreated with anti–IFN-α/β receptor Ab (10 μg/ml, Millipore) or 
15B-sap (8 ng/ml) for 30 minutes on ice, were stimulated with IFN-α 
(500 IU/ml, Millipore) or the HIV-R3B/A virus stock for 2 hours, and 
were then cultured for 72 hours. PBMCs from HC and HIV-1–infected 
subjects were preincubated with IFN-α (1000 IU/ml) or medium for 
16 hours. Then the spleen cells and PBMCs were collected and cul-
tured in complete RPMI (RPMI 1640 containing 10% heat-inactivat-
ed fetal bovine serum, 2 mM l-glutamine, 100 U/ml penicillin, and 
100 mg/ml streptomycin sulfate, Cellgro) in the presence or absence 
of plate-bound anti-CD95 mAb (5 μg/ml, clone CH11, Millipore) for 
12 and 6 hours, respectively. Cells were then harvested and stained 
for active caspase-3.
Quantification of plasma LPS and sCD14. Plasma LPS levels were 
quantified using the Limulus amebocyte lysate (LAL) assay accord-
ing to the manufacturer’s protocol. Briefly, samples were inactivated 
for 10 minutes at 75°C and incubated with LAL for 750 minutes at 
37°C. Addition of reagents led to formation of a magenta deriva-
tive that absorbs light at 570 nm. Plasma-soluble CD14 (sCD14) was 
quantified by ELISA (R&D Systems).
Immunohistochemistry. Immunohistochemistry was performed 
on formalin-fixed and paraffin-embedded 4-μm colon tissue sec-
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